MAM
CYTK icon

Melqart Asset Management’s Cytokinetics CYTK Stock Holding History

Melqart Asset Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-800,100
Closed -$56.1M – 58
2024
Q1 		$56.1M Buy
+800,100
New +$61.9M 3.5% 9

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Melqart Asset Management's CYTK Position: Q1 2026 in Review

Melqart Asset Management increased its Cytokinetics (CYTK) stake by 35% in Q1 2026, buying an estimated $14M and bringing the position to 843,949 shares worth $55.6M. The position accounts for 5.48% of the portfolio, ranked #4.

Melqart Asset Management first reported a position in CYTK in Q1 2024 and has held it in 9 quarters since. The position peaked at $90.8M in Q2 2024. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

  • Melqart Asset Management held 843,949 shares of Cytokinetics worth $55.6M as of Q1 2026.
  • Melqart Asset Management bought 221,051 Cytokinetics shares in Q1 2026, an estimated $14M.
  • Cytokinetics made up 5.48% of Melqart Asset Management's portfolio in Q1 2026, its #4 holding.
  • Melqart Asset Management first reported a position in Cytokinetics in Q1 2024 and has held it in 9 quarters since.
  • Melqart Asset Management's Cytokinetics position peaked at $90.8M in Q2 2024.
  • 439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Melqart Asset Management's 13F filing for Q1 2026, filed 12 May 2026.